Pembrolizumab activates innate immune metabolism and function in primary human non-small cell lung cancer, whereas Pembrolizumab and beta-glucan synergize in enhancing immune metabolism and tumoridical action in brain-metastasized lung cancer.

Integrated molecular analysis demonstrated that colorectal cancer can be classified into four molecular subtypes (proliferative, immunomodulatory, immunosuppressed, and immune-excluded subtypes), providing valuable insight into the intricate relationship between tumor microenvironment heterogeneity and various clinical phenotypes.

A new, high-throughput in vivo MHC-I peptide minigene library platform shows that the naive immune system cannot eliminate cells presenting immunogenic antigens found at low frequencies within a growing tumor.

Why does cancer develop in situations where the immune system is perfectly capable of eliminating it?

Single-cell RNA sequencing of biopsy samples from advanced-stage lung cancer reveals tumor and immune cell features associated with response to immune checkpoint therapy.

Chemotherapy remodels lung adenocarcinoma’s tumor microenvironment by driving metabolic reprogramming and shifting immune cell functions to modulate tumor progression and immune responses.

AIDPS derived by 76 machine-learning algorithm combinations in 13 independent multicenter cohorts exhibited superior capability than clinical traits and 86 published prognostic signatures and could serve as an ideal biomarker for stratified management and individualized treatment of pancreatic cancer.

CK21 emerges as a compelling candidate for pancreatic cancer treatment, and its capacity to target the NF-κB pathway, induce mitochondrial-mediated apoptosis, and do so with minimal toxicity is a significant stride in the quest for improved therapies.

In vivo modeling of neoantigen-restricted heterogeneity shows that clonal expression of neoantigens enhances anti-tumor T cell responses by increasing the stimulatory capacity of dendritic cells in the lymph node.

Drugs in a curative chemotherapy regimen are independently effective and resisted by different mechanisms, so cancer cells have little chance of surviving all drugs, and this benefit occurs without synergistic interactions.